Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: December 12, 2016
Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials.
Journal: Diabetes, obesity & metabolism
Published: June 02, 2016
Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.
Journal: Diabetes care
Published: June 21, 2014
Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine.
Journal: Diabetes care
Published: November 08, 2013
The effect of adjusting for baseline hypoglycemia when analyzing hypoglycemia data: a systematic analysis of 15 diabetes clinical trials.
Journal: Diabetes technology & therapeutics
Published: July 26, 2013
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study.
Journal: Diabetes care
Published: November 30, 2012
A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.
Journal: Diabetes care
Published: July 13, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026